Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53‐altered tumors-Reference-Cited by-同舟云学术

Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53‐altered tumors

Published:2019-04-23 Issue:14 Volume:125 Page:2409-2422
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Gunaratne Preethi H.¹²³⁴^ORCID,Pan Yinghong¹⁵,Rao Abhi K.⁶,Lin Chunru⁷,Hernandez‐Herrera Anadulce⁴,Liang Ke⁷,Rait Antonina S.⁶,Venkatanarayan Avinashnarayan⁷⁸,Benham Ashley L.¹⁹,Rubab Farwah¹⁰,Kim Sang Soo⁶¹⁰,Rajapakshe Kimal²,Chan Clara K.¹¹,Mangala Lingegowda S.¹²¹³,Lopez‐Berestein Gabriel¹³¹⁴,Sood Anil K.¹²¹³,Rowat Amy C.¹¹,Coarfa Cristian²,Pirollo Kathleen F.⁶,Flores Elsa R.⁷¹⁵,Chang Esther H.⁶¹⁰

Affiliation:

1. Department of Biochemistry and Biology University of Houston Houston Texas

2. Department of Molecular and Cell Biology Baylor College of Medicine Houston Texas

3. Human Genome Sequencing Center Baylor College of Medicine Houston Texas

4. Lester and Sue Smith Breast Center Baylor College of Medicine Houston Texas

5. UPMC Genome Center Pittsburgh Pennsylvania

6. Department of Oncology, Lombardi Comprehensive Cancer Center Georgetown University Washington District of Columbia

7. Department of Molecular and Cellular Oncology, Division of Basic Science The University of Texas MD Anderson Cancer Center Houston Texas

8. Genentech, Inc. South San Francisco California

9. 10X Genomics Inc. Pleasanton California

10. SynerGene Therapeutics, Inc. Potomac Maryland

11. Department of Integrative Biology and Physiology University of California Los Angeles California

12. Gynecologic Oncology and Reproductive Medicine The University of Texas MD Anderson Cancer Center Houston Texas

13. Center for RNAi and Non-Coding RNAs The University of Texas MD Anderson Cancer Center Houston Texas

14. Department of Experimental Therapeutics The University of Texas MD Anderson Cancer Center Houston Texas

15. Department of Molecular Oncology Cancer Biology and Evolution Program, Moffitt Cancer Center Tampa Florida

Funder

U.S. Public Health Service

Cancer Prevention and Research Institute of Texas

National Science Foundation

National Foundation for Cancer Research

National Cancer Institute

National Institutes of Health

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32053

Reference40 articles.

1. Cancer of the Ovary

2. Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects

3. Role of microRNAs in drug-resistant ovarian cancer cells

4. Integrated genomic analyses of ovarian carcinoma

5. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liposomal delivery of gene therapy for ovarian cancer: a systematic review;Reproductive Biology and Endocrinology;2023-08-23

2. Metal-Based Anticancer Complexes and p53: How Much Do We Know?;Cancers;2023-05-19

3. DNA Demethylation Switches Oncogenic ΔNp63 to Tumor Suppressive TAp63 in Squamous Cell Carcinoma;Frontiers in Oncology;2022-07-14

4. P63 and P73 Activation in Cancers with p53 Mutation;Biomedicines;2022-06-23

5. Research Progress of p63 Gene and Its Role in Cervical Cancer;Advances in Clinical Medicine;2022